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Abstract
Background: The melanin-concentrating hormone receptor 1 (MCHR1), which is highly expressed in the lateral
hypothalamus, plays a key role in energy homeostasis, obesity and other endocrine diseases. Hence, there is a
major interest in in vivo imaging of this receptor. A PET tracer would allow non-invasive in vivo visualization and
quantification of the MCHR1. The aim of the study was the ex vivo evaluation of the MCHR1 ligand [18F]FE@SNAP
as a potential PET tracer for the MCHR1.
Methods: [18F]FE@SNAP was injected directly into the jugular vein of awake naïve rats for ex vivo brain autoradiography,
biodistribution and additional blood metabolite analysis. Blocking experiments were conducted using the
unlabeled MCHR1 ligand SNAP-7941.
Results: A high uptake of [18F]FE@SNAP was observed in the lateral hypothalamus and the ventricular system. Both
regions were significantly blocked by SNAP-7941. Biodistribution evinced the highest uptake in the kidneys, adrenals,
lung and duodenum. Specific blocking with SNAP-7941 led to a significant tracer reduction in the heart and adrenals.
In plasma samples, 47.73 ± 6.1 % of a hydrophilic radioactive metabolite was found 45 min after tracer injection.
Conclusions: Since [18F]FE@SNAP uptake was significantly blocked in the lateral hypothalamus, there is strong
evidence that [18F]FE@SNAP is a highly suitable agent for specific MCHR1 imaging in the central nervous system.
Additionally, this finding is supported by the specific blocking in the ventricular system, where the MCHR1 is expressed
in the ependymal cells. These findings suggest that [18F]FE@SNAP could serve as a useful imaging and therapy
monitoring tool for MCHR1-related pathologies.
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Background
The melanin-concentrating hormone receptor 1 (MCHR1)
plays a key role in energy homeostasis and obesity [1, 2].
Furthermore, it has been implicated to be involved in
the pathogenesis of diabetes [3, 4] and inflammatory
processes in the gut [5]. Since obesity affects over
600 million individuals worldwide (as estimated by
the World Health Organization in 2014 [6]), there is
extensive pharmaceutical interest in the development
of anti-obesity drugs. It has been shown that MCHR1
antagonists reduce body weight in rodents [7]. Never-
theless, none of these molecules reached market
authorization so far. A MCHR1-positron emission
tomography (PET) ligand could support dose selection
of MCHR1 antagonists [7] and, therefore, would be a
valuable tool for drug development. PET allows non-
invasive in vivo visualization and quantification of
receptor systems, as well as monitoring and following
hormone receptor status and related pathologies in
vivo. Besides the application of a MCHR1-PET tracer
for compound dose selection of potential MCHR1-
targeting drugs, another potential implication for
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obesity patients could be the in vivo quantification of
the MCHR1—which is predominantly expressed in
the lateral hypothalamus [8]—as a risk factor and
early diagnostic tool for insulin resistance. Further-
more, a MCHR1-PET ligand could help to better
understand the endocrine status and guide pharmaco-
logical intervention via the MCHR1.
So far, based on the specific MCHR1 antagonist
SNAP-7941 [9], [11C]SNAP-7941 was developed as
the first PET tracer for the MCHR1 and was
evaluated in a preclinical study [10, 11]. Furthermore,
we introduced the 18F-fluoroethylated analogue
[18F]FE@SNAP (Fig. 1) as an alternative potential
PET tracer for the MCHR1 [12, 13]. [18F]FE@SNAP
showed a high affinity (Kd = 2.9 nM, evaluated on CHO
cells expressing the human MCHR1) and selectivity (Ki >
1000 nM on the second MCH receptor, MCHR2) towards
the MCHR1 [13].
After successful in vitro evaluation, the next logical
step in the preclinical evaluation process was the
performance of ex vivo experiments. Hence, the
purpose of the present study was to confirm the
potential of [18F]FE@SNAP for specific MCHR1 brain
imaging in healthy rats. Therefore, [18F]FE@SNAP
was administered IV for ex vivo brain autora-
diography and additionally to study biodistribution
and to search for potential circulating metabolites. It is
noteworthy that IV application was performed through
the jugular vein, allowing animals to be awake and
conscious, hence excluding the well-known significant
anaesthetic influence on imaging results [14–16].
Methods
Animals
With free access to tap water and standard laboratory
animal diet, 16-week-old male Sprague-Dawley rats
(436 ± 79 g, mean ± SD) were kept under controlled
environmental conditions on a 12-h light–12-h dark
cycle (Alleinfutter für Ratten und Maeuse sniff R/M-H,
sniff Spezialdiaeten GmbH; Soest, Germany).
For implantation with indwelling catheters into the
right jugular, rats were anaesthetized by an intraperi-
toneal injection of ketamine-xylazine supplemented, if
necessary, with inhalative sevoflurane [17]. Tracer
experiments were performed not earlier than 7 days
after surgery, when all rats were ±10 % within their
pre-surgical body weight. Since these catheters
allowed IV injections into conscious freely moving
rats, any influence of anaesthesia was excluded in
these experiments. All procedures and protocols using
animals have been approved by the Institutional
Animal Care and Use Committee of the Medical
University of Vienna, Austria, as well as by the
Austrian Ministry of Science, Research and Economy
(BMWF-66.009/0268-II/3b/2012).
Tracer preparation
Radiosyntheses of [18F]FE@SNAP and [18F]altanserin were
performed in a microfluidic device (Advion NanoTek®)
followed by a purification in a conventional synthesizer
(Nuclear Interface®) as described elsewhere [13].
[18F]FE@SNAP was formulated in physiological saline
solution (606 ± 332 MBq/500 ± 346 μL; formulation
volume depending on radiochemical yield).
IV study including biodistribution and metabolite analysis
Conscious and freely moving rats of the baseline and
blocking groups were always examined simultan-
eously: rats of the baseline group (n = 3) received ve-
hicle (400 μL), and rats of the blocking group (n = 3)
received SNAP-7941 (15 mg/kg; freshly dissolved in
400 μL) via the jugular vein 30 min prior to tracer
application. Via the jugular vein, 51.33 ± 26.2 MBq of
[18F]FE@SNAP (specific activity 12.3–43.1 GBq/μmol;
radiochemical purity ≥95 %; 30–100 μL) was then
administered to all rats. After 45 min, rats were
sacrificed by IV ketamine injection and decapitated,
and the brains were removed and immediately quick fro-
zen in isopentane (−45 °C) for ex vivo autoradiography.
Fig. 1 Chemical structure of [18F]FE@SNAP. Red colour indicates the radiolabel position
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Other organs including the eyes, tongue, muscle,
epidermal white adipose tissue (WATep), heart, lung,
stomach, pancreas, liver, duodenum, colon, spleen,
kidneys, adrenals, testis, bladder and bone as well as
blood and urine were removed, weighed and
measured in a gamma counter (2480 WIZARD2,
PerkinElmer). Radioactivity concentrations were nor-
malized to dose and weight and expressed as percent
injected dose per gram (%ID/g). To determine signifi-
cant differences, a two-tailed t test with α = 0.95 was
performed using the statistics add-on in Microsoft
Excel® 2013. A value of P < 0.05 was considered as
significant.
For analysis of potential circulating metabolites,
blood samples from the baseline group were collected
into heparinized tubes and immediately stored on ice
before processing. The blood was centrifuged (Hettich
Rotanta/TRC; 3400×g, 4 min) to separate cellular
components. Sample cleanup was performed by
vortexing plasma with the equivalent amount of
acetonitrile and by subsequent centrifugation (Hettich
Universal 30RF; 23,000×g, 3 min) to remove precipi-
tated proteins. The obtained supernatant was applied
to radio-thin-layer chromatography (radio-TLC silica
gel plates, mobile phase acetonitrile/water 70/30 v/v,
application volume 2 μL on origin) and analysed via a
Canberra-Packard Instant Imager.
Ex vivo autoradiography
Whole rat brains (n = 6) were cut in a cryo-microtome
(Microm HM 560, Thermo Scientific) into 50-μm-thick
slices and thaw-mounted onto superfrost slides (Menzel-
Gläser SUPERFROST® PLUS, Thermo Scientific). Samples
were placed on Phosphor Imager plates (Multisensi-
tive Phosphor Screens Long Type MS, PPN 7001724,
PerkinElmer) for an exposure period of 18 h and then
analysed with a Cyclone Phosphor Imager (Cyclone
Plus Storage Phosphor System, PerkinElmer). Data
analysis was performed with OptiQuant® data processing
software Version 5.0. Due to high-MCHR1 appearance,
special emphasis was laid on the hypothalamus [8]
and the ventricular system [18, 19]. Hence, regions of
interest (ROIs) were drawn for the hypothalamic re-
gion and the ventricle, and additionally, a non-target
region and the whole tissue were selected (Fig. 2). To
facilitate comparison, manually defined template ROIs
fitting to all slices (30 slices/brain; bregma −1.0 to
−2.5 mm) were applied. ROIs resulted in normalized
digital light units per square millimeter (DLU/mm2);
values were expressed as ratio of MCHR1-rich and
reference region. In detail, ratios of hypothalamus/
non-target and ventricle/non-target were calculated.
Significant differences were calculated as described
before.
Preliminary small-animal imaging
An anaesthetized rat (with 1.5–2.5 % isoflurane) was
immobilized in a multimodal animal carrier unit
(MACU; medres®—medical research GmbH, Cologne,
Germany) and maintained at a body temperature of 37 °C
throughout the whole experiment. [18F]FE@SNAP
(47.64 ± 1.23 MBq) was injected as a bolus via the
lateral tail vein, and dynamic PET imaging (Siemens
Inveon preclinical μPET/SPECT/CT system) was
performed over 60 min. Immediately afterwards, T1-
weighted high-resolution axial, coronary and sagittal
brain MRI scans were performed using a Bruker
BioSpec 94/30 USR small-animal MR system (Bruker
BioSpin GmbH, Karlsruhe, Germany).
Results
Ex vivo autoradiography after IV application of
[18F]FE@SNAP (baseline group, n = 3) showed tracer
uptake into the rat brains, with increased accumulation
in the lateral hypothalamus and the ventricular system.
In the blocking group (n = 3), whole-brain uptake was
significantly higher than in baseline animals. Specific
blocking with 15 mg/kg SNAP-7941 evinced a significant
reduction of tracer uptake in the lateral hypothalamus
and in the ventricular system (Fig. 3). The ratios are
shown in Table 1.
The results of the biodistribution (n = 3, each for
the “baseline” and the “blocking group”; 45 min after
injection) are shown in Fig. 4. Specific blocking with
15 mg/kg SNAP-7941 led to a significant tracer
Fig. 2 Scheme of the ROIs for calculation of ratios. 1 (yellow):
ventricular system; 2 (green): hypothalamic area; 3 (pink):
non-target region; and 4 (orange): whole brain. It is noteworthy
that ROIs 1 and 2 include the target areas as well as some
background areas, due to varying target size throughout the
different brain levels (bregma)
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reduction in the heart and adrenals. Other organs
known to express MCHR1 to some extent (eye,
tongue, muscle soleus, pancreas and colon) showed a
trend towards reduced uptake under blocking
conditions.
Analysis of metabolites in the blood (n = 3)
evinced 51.50 ± 5.5 % of the parent compound and
47.73 ± 6.1 % of a hydrophilic radioactive metabolite
(probably [18F]fluoroethanol) 45 min after tracer
application.
Preliminary small-animal PET measurements in a healthy
rat under baseline conditions showed a high tracer uptake
in the ventricular system (Fig. 5).
Discussion
Specific MCHR1 imaging is of high clinical interest
for status monitoring in endocrine pathologies like
obesity and diabetes. A PET tracer for MCHR1 com-
prises several advantages for clinicians and patients as
the in vivo monitoring and following of the hormone
receptor status and related pathologies. Moreover, it
could support dose selection of MCHR1 antagonists
in drug development [7].
The focus of this study was to investigate the potential
of [18F]FE@SNAP to specifically label MCHR1-rich
regions like the lateral hypothalamus [8]. Therefore,
[18F]FE@SNAP was injected IV into healthy and
conscious rats followed by ex vivo brain autoradiog-
raphy, biodistribution and analysis of potential blood
metabolites.
In order to avoid the well-known effects of anaesthesia
[14–16], [18F]FE@SNAP was administered directly into
the jugular vein of awake and conscious rats. IV applica-
tion of [18F]FE@SNAP showed a high and specific
uptake in the ventricular system—where the epen-
dymal cells are recently known to express the
MCHR1 [18, 19]—and the hypothalamic region sug-
gesting specific MCHR1 targeting and visualization.
Furthermore, blocking of MCHR1 with SNAP-7941
led to a significantly increased overall tracer uptake
into the brain, whilst significantly reducing tracer
uptake in the presumably MCHR1-rich regions. Since
MCHR1-rich regions are blocked with the unlabeled
SNAP-7941 and, therefore, specific MCHR1-targeted
binding was inhibited, an unspecific tracer uptake in
the whole brain was observed.
High specific blocking of the tracer in the brain was not
hampered by observed hydrophilic blood metabolites.
Apart from a high specific central MCHR1 uptake,
the blocking experiments hinted at a MCHR1-related
uptake of [18F]FE@SNAP also in the adrenals, eyes,
tongue, muscle, pancreas and colon which is in line
with literature [3, 20, 21]. However, statistical analysis
of the %ID/g of these organs only revealed specific
blocking in the adrenals. The specific blocking in the
heart raises the question whether MCHR1 might be
expressed there too.
With regard to future application of the tracer, it is
promising that no defluorination and insignificant
uptake of 18F-fluoride into the bone were observed.
It is noteworthy that throughout the jugular vein injec-
tion, rats were conscious during tracer application and
distribution; hence, potential influence of anaesthesia
was completely excluded. Therefore, specific binding
and blocking resulted directly from the investigated
compounds.
The high resolution of ex vivo autoradiography using a
Phosphor Imager allowed identification of specific
Table 1 Calculated ratios of the ROIs (DLU/mm2)
Ratio Baseline Blocking P values
Hypothalamus/non-target 2.14 ± 0.9 1.58 ± 0.5a 0.0004
Ventricle/non-target 2.20 ± 0.4 1.38 ± 0.2a <0.0001
aSignificant blocking
Fig. 3 Typical ex vivo brain autoradiography (bregma −2.30 mm) after injection of [18F]FE@SNAP into the jugular vein under baseline (a) and
blocking (b) with SNAP-7941 (15 mg/kg). Region 1: ventricular system; region 2: hypothalamic area including the third ventricle. Red arrows indicate
significantly reduced tracer uptake in both regions
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uptake of [18F]FE@SNAP in the lateral hypothalamus
and in the ependymal cells of the third ventricle epithe-
lium. Hence, as a consequential step, future small-
animal PET experiments are feasible.
Conclusions
Since the MCHR1 is predominantly expressed in the
lateral hypothalamus as well as in the ependymal cells
of the third ventricle epithelium, a tracer for the
MCHR1 should show specific uptake and be signifi-
cantly blocked by an unlabeled ligand in these areas.
[18F]FE@SNAP proved these characteristics, which
provides strong evidence that it is a highly specific
agent for MCHR1 imaging. Involvement of MCHR1
was reported in diabetes and obesity, and MCHR1
has also been related to asthmatic seizures, colitis,
depression, anxiety and promotion of sleep. Against
this background, [18F]FE@SNAP could serve as a use-
ful tool for imaging and therapy monitoring for
MCHR1-related pathologies.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CP conducted the radiosynthesis, ex vivo autoradiography,
biodistribution and blood metabolite analysis; interpreted the results;
and wrote the manuscript. DH conducted the ex vivo autoradiography
and biodistribution experiments; interpreted the results; and
contributed to the writing of the manuscript. TS performed the IV
application of the tracer; sacrificed the animals; and removed the
organs. CF implanted the catheters into the right jugular vein of the
animals; did the IV application; sacrificed the animals; and removed the
organs. MZ performed the first small-animal PET/MR pilot scan. WW
contributed to the analysis of the experiments as well as to the
writing of the manuscript. KS synthesized the precursor and reference
compounds. HS contributed to the synthesis design of the reference
compounds and precursor. MH contributed to the design of the
experiments. MM interpreted the results and contributed to the writing
of the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This scientific project was performed with the support of the Medical Imaging
Cluster of the Medical University of Vienna.
Funding
This study was funded by the Austrian Science Fund (FWF P20977-B09,
FWF P26766).
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Fig. 4 Biodistribution of [18F]FE@SNAP. Experiments conducted 45 min after injection in healthy rats under baseline and blocking (15 mg/kg
SNAP-7941) conditions. Bars represent arithmetic mean ± standard deviation. If not visible, error bars are within the margin of the symbols.
Asterisk indicates significance
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